A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers

Approximately 50% of high-grade serous ovarian cancers (HGSOCs) have defects in genes involved in homologous recombination (HR) (i.e., BRCA1/2). Preclinical models to optimize therapeutic strategies for HR-deficient (HRD) HGSOC are lacking. We developed a preclinical platform for HRD HGSOCs that inc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JCI Insight
Autori principali: George, Erin, Kim, Hyoung, Krepler, Clemens, Wenz, Brandon, Makvandi, Mehran, Tanyi, Janos L., Brown, Eric, Zhang, Rugang, Brafford, Patricia, Jean, Stephanie, Mach, Robert H., Lu, Yiling, Mills, Gordon B., Herlyn, Meenhard, Morgan, Mark, Zhang, Xiaochen, Soslow, Robert, Drapkin, Ronny, Johnson, Neil, Zheng, Ying, Cotsarelis, George, Nathanson, Katherine L., Simpkins, Fiona
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2017
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5214535/
https://ncbi.nlm.nih.gov/pubmed/28097235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.89760
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi